5 best EDC platforms for Australian and ANZ clinical trials in 2026

Your data manager is three weeks from first patient in, still waiting on a Human Research Ethics Committee (HREC) review, and the eCRF isn't locked because your electronic data capture (EDC) vendor's build queue sits with a team nine time zones away. That gap between ANZ trial timelines and offshore vendor support cycles is the single biggest operational risk for sponsors and contract research organizations (CROs) in the region. This comparison reviews five EDC software platforms against what matters most here: build speed, support across time zones, compliance alignment, and total cost of ownership as volume grows. Viedoc leads on right-sized speed and self-sufficiency for teams that can't afford to wait on an overseas queue.

You're rarely running a single-country trial. Most ANZ-based CROs and growth-stage sponsors also run US or European sites in the same portfolio, so your platform must satisfy the Therapeutic Goods Administration (TGA) pathway and HREC sign-off locally while holding up under a Food and Drug Administration (FDA) or European Medicines Agency (EMA) audit elsewhere. With a lean team covering several studies at once, every hour spent waiting on a vendor-side programmer for a routine amendment doesn't come back.

Enterprise EDC platforms built for large, multi-year Phase III programs carry a level of complexity most ANZ CROs and mid-size sponsors don't need and can't easily staff for. Build and amendment cycles on these platforms typically depend on vendor-side programmers working to a change-control queue, adding time to a process a smaller, more agile team could otherwise finish in days. What ANZ-based teams need instead is a platform that lets in-house staff configure and amend studies directly, backed by support that doesn't assume everyone works US or European hours.

Best EDC solutions: quick comparison

These five eClinical platforms represent the most evaluated options for CROs and growth-stage sponsors running trials in Australia and New Zealand, reviewed across build speed, compliance alignment, support model, and total cost of ownership.

1. Viedoc

Viedoc's EDC software has run more than 8,000 clinical trials across more than 75 countries, the breadth of real-world use ANZ evaluation committees look for from an established vendor. The difference shows up after the sale: builds run through a no-code Designer that in-house data managers operate directly, with professional-services builds typically completed in 8–12 weeks and averaging 10. That self-sufficiency carries through mid-study amendments, which complete in as little as 1–3 working days for minor updates.

For CRO teams juggling multiple studies, Viedoc's CRO Program gives certified partners a preferred-vendor pathway built around that build speed. For sponsors handling biopharma clinical trial data collection, unlimited user seats mean adding sites across Australia and New Zealand carries no extra license cost.

Viedoc is ISO 27001 and SOC 2 certified, and supports FDA 21 CFR Part 11, the International Council for Harmonisation's Good Clinical Practice guideline (ICH GCP), EU Annex 11, the EU's General Data Protection Regulation (GDPR), and Health Insurance Portability and Accountability Act (HIPAA) attestation, covering the compliance stack an ANZ trial is likely to touch once US or European sites are involved. The Viedoc Inspection Readiness Packet (VIRP) gives quality assurance teams a structured audit-readiness reference. Support runs 24/7 across Viedoc's global offices, so a query raised at day's end doesn't sit untouched until the next one.

Pragathi G., an Enterprise-segment reviewer on G2, described the training impact directly. "Viedoc takes less time to train designers because of its uncomplicated functions and structure."

• Study scale: More than 8,000 studies run on Viedoc across 75-plus countries.
• User base: 140,000-plus users and 30,000-plus sites globally.
• Build speed: Professional-services study builds typically completed in 8–12 weeks, averaging 10.
• Uptime: 99.99% platform uptime, hosted on Microsoft Azure.
• Compliance: FDA 21 CFR Part 11, ICH GCP, EU Annex 11, GDPR, and HIPAA attestation; ISO 27001 and SOC 2 certified.
• Support: 24/7 support across Viedoc's global offices.

2. Medidata

Medidata offers Rave, the electronic data capture product at the center of the Medidata Platform, used to aggregate and reconcile data from eConsent, electronic clinical outcome assessment (eCOA), randomization and trial supply management (RTSM), and imaging sources into a single system. Rave supports mid-study protocol amendments without system downtime, migrating subject data from one form or protocol version to a new one as changes are approved. The platform connects to Medidata's broader suite, including Clinical Data Studio for centralized data-quality oversight and Rave Companion, which populates EDC forms directly from electronic health record (EHR) data. Medidata also offers Rave Lite, a scaled-down configuration aimed at Phase I, Phase IV, and post-market device studies. The company states the platform was named the most preferred EDC system in an independent 2025 sponsor benchmarking survey.

3. Veeva Vault EDC

Veeva provides Vault EDC as part of its Vault Clinical Data Management (CDMS) suite, combining electronic data capture with coding, data cleaning, and reporting on a single cloud platform. The system includes an in-product specification studio for designing complex study structures, including master protocols and adaptive designs, and role-based interfaces intended to speed source data verification (SDV) and medical assessment tasks. Vault EDC connects to other Veeva Vault applications, such as randomization and trial supply management and clinical trial management system (CTMS) modules, through prebuilt Veeva Connections that share data between them automatically. Veeva positions the product for sponsors already operating within the broader Vault ecosystem rather than as a standalone EDC purchase.

4. Castor EDC

Castor EDC is an API-driven electronic data capture platform that runs EDC and eCOA on a single database, aiming to remove the integration work of connecting separate systems. The platform includes a low-code eCRF builder for study design, and Castor reports that low-complexity studies can be deployed in as little as 3–4 weeks. Castor also supports electronic consent (eConsent), electronic patient-reported outcomes (ePRO), and interactive web response system (IWRS) modules alongside its core EDC, and integrates with EHR, laboratory, and wearable device data sources through an open API. Castor's site states the platform supports 21 CFR Part 11 and GDPR-aligned workflows, and the company markets it primarily toward decentralized and hybrid trial designs.

5. Medrio

Medrio provides a clinical data management system (CDMS) and EDC built for small and scaling clinical teams, combining a no-code study builder with both online and offline data capture. Sites without reliable internet access can continue entering data offline and sync once connectivity returns, a workflow Medrio positions for studies at remote or lower-connectivity locations. The platform includes an always-on testing environment intended to let teams validate mid-study changes and deploy them without a separate data migration step. Medrio states its system complies with 21 CFR Part 11, HIPAA, and Good Clinical Practice (GCP) requirements, and the company has supported studies for small and scaling sponsors and CROs since 2005.

What to look for in EDC solutions for Australian and ANZ clinical trials

Build speed that survives a lean data management team

A study build in Australia or New Zealand rarely has the luxury of a dedicated in-house programmer on staff, so the platform's build model matters more than the headline build-time figure. If every eCRF change has to route through a vendor's offshore queue, a routine amendment can stretch into weeks rather than days, and that delay compounds across a portfolio of concurrent studies.

Best-in-class platforms let a data manager configure and test changes directly, with minor updates completed in a few working days rather than a change-control cycle measured in weeks.

A platform that requires vendor programming for every amendment quietly caps how many studies a small team can run at once.

Compliance alignment across more than one regulatory regime

Most ANZ trials aren't purely local. A sponsor running a study out of Sydney or Auckland is often also managing US or European sites in the same protocol, so the platform needs to satisfy the TGA notification pathway and HREC oversight alongside FDA and EMA expectations elsewhere in the trial.

Look for a platform that holds ISO 27001 and SOC 2 certification alongside FDA 21 CFR Part 11, ICH GCP, EU Annex 11, GDPR, and HIPAA compliance as standard, rather than as a paid add-on for specific regions.

A platform that only satisfies one regulatory regime forces a sponsor to run parallel systems or manual workarounds the moment a trial expands beyond ANZ.

Support hours that match your time zone, not the vendor's

A support desk that only operates during US or European business hours is closed for most of an Australian or New Zealand working day, which matters most at moments that can't wait, like database lock or a site activation issue.

The platforms worth shortlisting offer 24/7 support with a direct escalation path, not a ticket queue that resets overnight.

Scalability across a large, low-density geography

Australia's site network is spread across a small number of major cities and a much larger number of remote and regional locations, which makes site activation and patient travel a bigger operational cost than in a densely populated European trial footprint.

A platform that supports decentralized clinical trials capability, remote consent, and televisit-style data collection reduces how often a participant needs to travel to a metropolitan site, which matters for recruitment and retention in regional Australia and New Zealand.

Platforms without this capability push the travel and coordination burden entirely onto the site team.

Pricing that doesn't penalize a growing study portfolio

A per-seat or per-module pricing model gets more expensive exactly when a CRO or sponsor is trying to scale, since every new site, clinical research associate (CRA), or data manager added to a study adds to the bill.

Transparent, study-based licensing with unlimited user seats keeps the cost predictable as a data management team, CRO network, or sponsor's trial portfolio grows across the region.

How to choose the right EDC solution for Australian and ANZ clinical trials

Step 1: Define your regulatory footprint before you shortlist

Work out whether this study, and the ones likely to follow it, stay within Australia and New Zealand or extend into US or European sites. A platform that's only ever been used for single-country ANZ trials may not hold the full compliance stack a multi-region protocol needs later.

Step 2: Assess how much you actually want to build in-house

Decide how much of the study build and amendment process your own data management team wants to own versus hand to a vendor's professional services. This changes which platforms are viable, since a no-code, self-service model only pays off if your team has the bandwidth and training to use it.

Step 3: Scrutinize the support model against your actual working hours

Ask a shortlisted vendor what their support coverage looks like at 9 a.m. Sydney time on a Saturday, not what it looks like on a sales call. A platform with support built around US or European hours will leave gaps exactly when an ANZ team needs a fast answer.

Step 4: Evaluate total cost as your study volume grows, not just at signature

Model what a per-seat or per-module platform would cost once you've added three more studies and doubled your site count, not just the cost of the first trial. Pricing that looks competitive at a single-study scale can compound quickly across a growing portfolio.

Step 5: Choose a platform built for the pace and structure of ANZ trial teams

If self-sufficiency, 24/7 support, and predictable costs matter more than a legacy brand name, Viedoc's EDC software is built for exactly that combination. Book a demo or request a proposal to see how a study build would run against your own protocol and timeline.

Frequently asked questions

What is the best EDC platform for Australian and ANZ clinical trials?

Viedoc's EDC software is the strongest fit for most CROs and growth-stage sponsors running trials in Australia and New Zealand, combining a no-code Designer that in-house teams can operate directly with 24/7 support that doesn't assume US or European business hours. Study builds through Viedoc's professional services typically complete in 8–12 weeks, averaging 10, with unlimited user seats and no per-user fees as a study portfolio grows. Medidata remains the default choice for large-scale, multi-year Phase III programs at major pharmaceutical companies, though its build and change-control process is built around that scale rather than a lean ANZ team. Castor EDC is a reasonable alternative for smaller, decentralized-trial-focused studies, particularly where fast, low-complexity deployment matters more than suite depth.

What should I look for when choosing an EDC platform for trials in Australia and New Zealand?

Prioritize a build model your own data management team can operate without depending on a vendor's offshore programming queue, since amendment speed matters more day to day than headline build-time figures. Confirm the platform holds compliance credentials that cover both the TGA and HREC requirements you'll face locally and the FDA, EMA, or other regulatory expectations that apply if the same protocol runs sites outside the region. Check the support model against your own working hours rather than the vendor's, and model total cost across a growing study portfolio, not just a single trial.

How long does it take to build and deploy a clinical study on a modern EDC platform?

Timelines vary by platform and by how much of the build a data management team handles in-house versus a vendor's professional services team. Self-service builds on a no-code platform can go live in as little as one day for straightforward studies, while a professional-services-managed build more typically takes 8–12 weeks, averaging around 10. Platforms built for large-scale enterprise programs generally run longer, since their build and change-control process is designed around complex, multi-year Phase III protocols rather than speed.

Which compliance certifications matter most for EDC platforms used in ANZ trials?

ISO 27001 and SOC 2 certification demonstrate the platform's own information security posture, which quality assurance and compliance teams typically check first. FDA 21 CFR Part 11 compliance and ICH GCP alignment cover electronic signature and audit trail requirements that apply broadly, including to the standards Australia's TGA and HRECs expect trial sponsors to follow. If the same protocol includes European or US sites, EU Annex 11, GDPR, and HIPAA compliance become relevant as well, so it's worth confirming these are included as standard rather than sold separately.

How does Viedoc's study build time compare to Medidata's?

Viedoc's professional-services study builds typically complete in 8–12 weeks, averaging 10, with self-service builds on the no-code Designer going live in as little as one day for simple studies. Medidata Rave EDC is built for large, complex, multi-year enterprise programs, and its build and change-control process is designed around that scale, which typically means a longer cycle than a lean ANZ study needs. For CROs and growth-stage sponsors who need to move faster without sacrificing compliance, that difference in build philosophy, not just speed, is often the deciding factor.

What is the difference between per-seat and per-study EDC licensing?

Per-seat licensing charges based on the number of users who need platform access, which means the bill grows every time a CRA, data manager, or site coordinator is added to a study. Per-study or study-based licensing charges for the study itself, with unlimited user seats included, so adding team members doesn't change the cost. For a CRO or sponsor running several concurrent studies, per-study licensing is generally the more predictable model as a trial portfolio scales.

Making the right EDC choice for Australian and ANZ clinical trials

The platforms compared here share a baseline of secure, browser-based data capture and audit trail support, but differ sharply in how much of the build sits with the vendor versus the customer. The global eClinical software market is estimated at more than $11 billion in 2025, projected to roughly double by 2030, with Asia-Pacific the fastest-growing region as trial volume shifts beyond the US and Western Europe.

Matching a platform to your situation starts with size and study complexity: a lean CRO or growth-stage sponsor running Phase I or Phase II studies generally needs speed and self-sufficiency more than the configurability a mega-trial requires. Compliance scope matters just as much, since a single-country ANZ study has a narrower requirement than a protocol also running European or US sites. US-based buyers tend to weight speed and return on investment most heavily, while EMEA, APAC, and ANZ buyers weight compliance credentials and vendor stability more heavily.

Switching platforms mid-portfolio carries a real validation and retraining cost, so it's worth weighing fit for your next three studies, not just the one in front of you.

Why Viedoc is the best EDC choice for Australian and ANZ clinical trials

Viedoc's EDC software has run more than 8,000 clinical trials across more than 75 countries, giving CROs and growth-stage sponsors in Australia and New Zealand a platform with the depth of use an evaluation committee expects from an established vendor, without the multi-month build cycle that often comes with it.

The no-code Designer lets your own data management team build and amend studies directly, unlimited user seats mean adding sites or staff doesn't add to the license cost, and 24/7 support across Viedoc's global offices covers the hours an ANZ-based team actually works. A tiered CRO Program gives certified partners a preferred-vendor pathway, and certified Designer training gets a new team member building studies independently within days.

Viedoc is ISO 27001 and SOC 2 certified, supports FDA 21 CFR Part 11, ICH GCP, EU Annex 11, GDPR, and HIPAA attestation, and provides the VIRP to every customer as a standing audit-readiness reference. Founded in Uppsala, Sweden, in 2003, Viedoc has more than two decades of production use behind its compliance posture, not a roadmap promise.

If your team is ready to see how a study build against your own protocol would actually run, book a demo or request a proposal and we'll walk through build speed, compliance coverage, and support model in the context of your ANZ trial portfolio.